Dacliximab or daclizumab

Anti-Bid Antibody has been tested for use in ELISA, Western Blotting, Immunohistochemistry and Immunofluorescence. Specific conditions for reactivity should be optimized by the end user.

Brentuximab vedotin (anti-CD30) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin (anti-CD30) can be used for the research of relapsed and refractory

Brentuximab vedotin (anti-CD30) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin (anti-CD30) can be used for the research of relapsed and refractory

Brentuximab vedotin (anti-CD30) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin (anti-CD30) can be used for the research of relapsed and refractory

Brentuximab vedotin (anti-CD30) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin (anti-CD30) can be used for the research of relapsed and refractory

Camidanlumab (anti-CD25) is a CD25 monoclonal antibody. Camidanlumab (anti-CD25) targets the cell-surface antigen CD25, which is over-expressed on a variety of hematological tumors and shows limited expression on normal tissues.

Camidanlumab (anti-CD25) is a CD25 monoclonal antibody. Camidanlumab (anti-CD25) targets the cell-surface antigen CD25, which is over-expressed on a variety of hematological tumors and shows limited expression on normal tissues.

Camidanlumab (anti-CD25) is a CD25 monoclonal antibody. Camidanlumab (anti-CD25) targets the cell-surface antigen CD25, which is over-expressed on a variety of hematological tumors and shows limited expression on normal tissues.

Camidanlumab (anti-CD25) is a CD25 monoclonal antibody. Camidanlumab (anti-CD25) targets the cell-surface antigen CD25, which is over-expressed on a variety of hematological tumors and shows limited expression on normal tissues.

Host: mouse, clone 203.6 Cross Reactivity: (+) human CD27 Application(s): FC, ICC, and IHC (frozen sections) (&minus) WB

Armenian Hamster anti Human CD278/ICOS Antibody, Monoclonal (C398.4A), could be used for Flow and so on.

CTLA4 or CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), also known as CD152 (cluster of differentiation 152), is a protein receptor that, functioning as an immune checkpoint, downregulates immune responses. CTLA4 is constitutively expressed